Cargando…

Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States

Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database was designed to estimate the prevalence of re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Yi, Bhowmik, Debajyoti, Bond, Christopher, Wang, Steven, Colman, Sam, Hernandez, Rohini K., Cheng, Paul, Intorcia, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504317/ https://www.ncbi.nlm.nih.gov/pubmed/28612485 http://dx.doi.org/10.1002/cam4.1075

Ejemplares similares

Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
por: Arellano, Jorge, et al.
Publicado: (2015)

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
por: Qian, Yi, et al.
Publicado: (2017)

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States
por: McGrath, Leah J., et al.
Publicado: (2018)

Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma
por: Kobayashi, Hiroki, et al.
Publicado: (2020)

The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model
por: Wertman, Jaime N, et al.
Publicado: (2020)

Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016
por: Ellington, Taylor D., et al.
Publicado: (2020)

Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma
por: Olszewski, Adam J., et al.
Publicado: (2019)

Differential effects of nephrotoxic agents on renal transport and metabolism by use of in vitro techniques.
por: Hirsch, G H
Publicado: (1976)

Nephrotoxicity of recent anti-cancer agents
por: Lameire, Norbert
Publicado: (2014)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media
por: Michael, Ashour, et al.
Publicado: (2014)

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Pharmacological agents for the prevention of colistin-induced nephrotoxicity
por: Mirjalili, Mahtabalsadat, et al.
Publicado: (2022)

Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma
por: Li, Suying, et al.
Publicado: (2020)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
por: Tandon, Vasudha, et al.
Publicado: (2022)

Non-invasive detection of corneal sub-basal nerve plexus changes in multiple myeloma patients by confocal laser scanning microscopy
por: Koschmieder, Anita, et al.
Publicado: (2020)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set
por: Edbrooke, Lara, et al.
Publicado: (2023)

Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity
por: Ojha, Shreesh, et al.
Publicado: (2016)

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents
por: Hong, Min Hee
Publicado: (2021)

S-nitrosothiols and H(2)S donors: Potential chemo-therapeutic agents in cancer
por: Reis, Adriana Karla Cardoso Amorim, et al.
Publicado: (2019)

Adefovir nephrotoxicity in a renal allograft recipient
por: George, N., et al.
Publicado: (2015)

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
por: Radocha, Jakub, et al.
Publicado: (2018)

Epidemiology of multiple myeloma in 17 Latin American countries: an update
por: Curado, Maria Paula, et al.
Publicado: (2018)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Combination therapy using molecular‐targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma
por: Kitano, Hiroyuki, et al.
Publicado: (2017)

Serum markers change for intraocular metastasis in renal cell carcinoma
por: Sun, Tie, et al.
Publicado: (2021)

20(S)-ginsenoside Rh2 as agent for the treatment of LMN-CRC via regulating epithelial–mesenchymal transition
por: Yuan, Yihang, et al.
Publicado: (2020)

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
por: Paul, Barry, et al.
Publicado: (2020)

Cisplatin-Induced Nephrotoxicity and HIV Associated Nephropathy: Mimickers of Myeloma-Like Cast Nephropathy
por: Khurram, Muhammad Siddique, et al.
Publicado: (2017)

Renal protective effect of selenium on cisplatin-induced nephrotoxicity
por: Ghorbani, Ali
Publicado: (2012)

Protection of renal tubules against gentamicin induced nephrotoxicity
por: Tavafi, Majid
Publicado: (2013)

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients
por: Zununi Vahed, Sepideh, et al.
Publicado: (2015)

Renal protective effect of polysulfide in cisplatin-induced nephrotoxicity
por: Cao, Xu, et al.
Publicado: (2018)

Renal Lesions and Nephrotoxicity: Contemporary Challenges and Future Directions
por: Plotnikov, Egor
Publicado: (2023)

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
por: Kumar, Lalit, et al.
Publicado: (2019)

The mechanism study of miR‐125b in occurrence and progression of multiple myeloma
por: Gao, Da, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pdeqc14veh4lcnge7ls156uqrf